ISIS-TTR Rx Articles
GSK pays $7.5 million milestone to Isis Pharma under antisense deal; says FDA accepts Anoro Ellipta NDA
20 February 2013
Showing 1-1 of 1 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
